BeiGene Acquires Antibody Drug Conjugate Rights From DualityBio And Nona Biosciences

Nona Biosciences is a leading global biotech company that provides comprehensive services from idea to IND (I to IND™). The firm has confirmed that China’s BeiGene, Ltd has decided to launch global development, manufacturing, and marketing rights for an Antibody Drug Conjugate from DualityBio, a collaborator of Nona Biosciences.

The ADC was developed under a working cooperation between Nona Biosciences and DualityBio and launched in 2022. As part of this agreement, Nona Biosciences granted DualityBio a preferred license to certain monoclonal antibodies relevant to specific tumours for creating novel, first-in-class ADC assets with international applications.